Vernalis is a development stage pharmaceutical company with significant expertise both in de novo fragment and structure-based drug discovery and pre-clinical and clinical development.

The Group has one marketed product, frovatriptan for the acute treatment of migraine, and five priority product candidates in clinical development (three of which are partnered), two further priority programmes in pre-clinical development (neither of which is partnered) and other collaborative drug discovery programmes. .

Vernalis has a further two partnered programmes that are in clinical development in which it retains an economic interest. Our technologies, capabilities and products are endorsed by collaborations with leading, global pharmaceutical companies including GSK, Biogen Idec, Novartis, Servier, Chiesi, Menarini, and Endo. 

Product Pipeline

To find out more details of the conditions we are seeking to treat: view our product pipeline.



Latest News

08/03/2010
Vernalis Regains European Rights to Frovatriptan

11/02/2010
Placing and Open offer February 2010

Share Price

GBp   74.50   0.00       Time Last Trade 11:21 GMT
Vernalis Mini Chart